FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease

Figure 1 Management decisions following fecal calprotectin testing. Proportion of patients for each of the possible management options, A: When the fecal calprotectin (FC) test caused physicians to change the management of their patient (n = 143); B: When the FC test did NOT cause a change in patient management (n = 136).

Figure 2 Impact of positive or negative fecal calprotectin result on management. Comparison of the percentage of patients undergoing a change in management as a function of whether the fecal calprotectin (FC) result was positive (> 250 μg/g) or negative (< 250 μg/g). Patients were significantly more likely to have a change in management when the FC result was positive (P < 0.0001).

Figure 3 Impact of positive or negative fecal calprotectin result on colonoscopy occurrence. Reduction in colonoscopies planned as a result of the availability of the fecal calprotectin test. There was a significant reduction in colonoscopies planned (P < 0.001). FC: Fecal calprotectin.

Figure 4 Outcomes of follow-up patient subset. Clinical outcomes in the follow-up subgroup according to FC result. FC: Fecal calprotectin; IBD: Inflammatory bowel disease.